Coming Soon – October 2019 MARKET OUTLOOK Rituximab-based...
Coming Soon – October 2019 MARKET OUTLOOK Rituximab-based chemoimmunotherapy regimens (e.g...
MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy...
MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy despite the availability of several treatment options. Resistance to therapy is the primary trea......
MARKET OUTLOOK Myelodysplastic syndromes (MDS) are a heterogeneous...
MARKET OUTLOOK Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stemcell disorders that res......
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has...
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Histor......
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in...
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. ...
The launch of several novel therapies, as well as multiple label expansions of...
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (...
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over...
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have......
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has...
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historic......
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of...
Market Outlook: Non-Hodgkin’s lymphoma (NHL) encompasses a plethora of subtypes with varying prognoses and drug-treatment options. MabThera remains at the heart of...
MARKET OUTLOOK. Myelofibrosis is a hematological malignancy characterized by...
MARKET OUTLOOK. Myelofibrosis is a hematological malignancy characterized by the disrupted production of blood cells and bone marrow scarring; symptoms include severe anemia, wea......
Market Outlook Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s...
Market Outlook Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label...
Market Outlook The most important clinical distinction in the first-line...
Market Outlook The most important clinical distinction in the first-line treatment of multiple myeloma is determining whether the patient is eligible to undergo autologo......
MARKET OUTLOOK Acute myeloid leukemia (AML) is the most common and...
MARKET OUTLOOK Acute myeloid leukemia (AML) is the most common and aggressive form of leukemia in adults, with the lowest sur......
Introduction: Non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of...
Introduction: Non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of malignancies that can be broadly classified into...
Treatment Sequencing provides disease-specific, sequential treatment patterns...
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing an......
Myelodysplastic syndromes ( MDS ) is a heterogeneous collection of hematopoietic...
Myelodysplastic syndromes ( MDS ) is a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenias and risk of progression to acute myeloid leukemia ( AML ). Management......
Market Outlook Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s...
Market Outlook Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven si......
The launch of several novel therapies, as well as multiple label expansions of...
The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma ( NHL ) therapy market over the ten-......
Chronic myeloid leukemia is a slow progressive tumor, characterized by...
Chronic myeloid leukemia is a slow progressive tumor, characterized by different phases of disease (chronic, accelerated, and blast). Treatment of chronic myeloid leukemia is dominated by oral BC......
Incyte/Novartis’s Jakafi/Jakavi (ruxolitinib) is the first and only drug...
Incyte/Novartis’s Jakafi/Jakavi (ruxolitinib) is the first and only drug approved for MF in the United States (2011) and EU5 (2012). While Jakafi/Jakavi offers a therapeutic option for patients wit......
